To test if the presence of HLA‐A*02 impacts anti‐tumoral immunity in EBV+cHL, we assessed ex‐vivo responses to relevant EBV latency antigens in pretherapy cHL patients. Here, HLA-A is linked to classic Hodgkin lymphoma.